Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis

被引:20
|
作者
Okano, M. [1 ]
Otsuki, N. [2 ]
Azuma, M. [2 ]
Fujiwara, T. [1 ]
Kariya, S. [1 ]
Sugata, Y. [1 ]
Higaki, T. [1 ]
Kino, K. [3 ]
Tanimoto, Y. [4 ]
Okubo, K. [5 ]
Nishizaki, K. [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Otolaryngol Head & Neck Surg, Okayama 7008558, Japan
[2] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
[3] Meiji Dailies Corp, Div Res & Dev, Odawara, Japan
[4] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Resp Med, Okayama 7008558, Japan
[5] Nippon Med Sch, Dept Otolaryngol, Tokyo 113, Japan
来源
CLINICAL AND EXPERIMENTAL ALLERGY | 2008年 / 38卷 / 12期
关键词
allergen immunotherapy; allergic rhinitis; BTLA; Cry j 1; IL-5;
D O I
10.1111/j.1365-2222.2008.03116.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
B7/CD28 family co-signalling molecules play a key role in regulating T cell activation and tolerance. Allergen-specific immunotherapy (SIT) alters allergen-specific T cell responses. However, the effect of SIT on the expression of various co-signalling molecules has not been clarified. We sought to determine whether SIT might affect the expression of three co-inhibitory molecules, programmed death (PD)-1, B7-H1 and B and T lymphocyte attenuator (BTLA), in Japanese cedar pollinosis (JCP). Peripheral blood mononuclear cells (PBMCs) were isolated from JCP patients who had or had not received SIT. PBMC were cultured in the presence or absence of Cry j 1, after which the cell surface expression of PD-1, B7-H1 and BTLA, as well as IL-5 production, were determined. In addition, the effect of BTLA cross-linking on IL-5 production was examined. After Cry j 1 stimulation, no significant differences in PD-1 and B7-H1 expression were observed between SIT-treated and SIT-untreated patients. BTLA expression was down-regulated in untreated patients after Cry j 1 stimulation and up-regulated in SIT-treated patients. Up-regulation of BTLA in SIT-treated patients was particularly apparent in a CD4(+) T cell subset. IL-5 production was clearly reduced among SIT-treated patients, and the observed changes in BTLA expression correlated negatively with IL-5 production. Moreover, immobilization of BTLA suppressed IL-5 production in JCP patients. These results suggest that both IL-5 production and down-regulation of BTLA in response to allergen are inhibited in SIT-treated patients with JCP. BTLA-mediated co-inhibition of IL-5 production may contribute to the regulation of allergen-specific T cell responses in patients receiving immunotherapy. Cite this as: M. Okano, N. Otsuki, M. Azuma, T. Fujiwara, S. Kariya, Y. Sugata, T. Higaki, K. Kino, Y. Tanimoto, K. Okubo and K. Nishizaki, Clinical and Experimental Allergy, 2008 (38) 1891-1900.
引用
收藏
页码:1891 / 1900
页数:10
相关论文
共 50 条
  • [41] CD27 expression on allergen-specific T cells: A new surrogate for successful allergen-specific immunotherapy?
    Gilles, Stefanie
    Traidl-Hoffmann, Claudia
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : 552 - 554
  • [42] Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis
    Li, Yan
    Xiao, Haiqing
    Zeng, Yinhui
    Tang, Yiquan
    Zhou, Lifeng
    Liu, Wenlong
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2024, 23 (01) : 52 - 58
  • [43] Effect of intralymphatic allergen-specific immunotherapy on house dust mite in a murine model of allergic rhinitis
    Jung, Joo Hyun
    Kim, Kyeong Ah
    Choi, Yun Sook
    Kim, Seon Tae
    ACTA OTO-LARYNGOLOGICA, 2023, 143 (10) : 867 - 875
  • [44] Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
    Pfaar O.
    Gerth van Wijk R.
    Current Treatment Options in Allergy, 2015, 2 (1) : 1 - 9
  • [45] GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma
    Zuberbier, T.
    Bachert, C.
    Bousquet, P. J.
    Passalacqua, G.
    Canonica, G. Walter
    Merk, H.
    Worm, M.
    Wahn, U.
    Bousquet, J.
    ALLERGY, 2010, 65 (12) : 1525 - 1530
  • [46] Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific Immunotherapy in Murine Allergic Rhinitis
    Shin, Ji-Hyeon
    Kim, Do Hyun
    Kim, Boo-Young
    Kim, Sung Won
    Hwang, Se Hwan
    Lee, Joohyung
    Kim, Soo Whan
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2017, 9 (03) : 237 - 246
  • [47] Upregulated levels of human -defensins in patients with seasonal allergic rhinitis after allergen-specific immunotherapy treatment
    Bogefors, Jesper
    Kvarnhammar, Anne Mansson
    Cardell, Lars-Olaf
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2013, 3 (02) : 99 - 103
  • [48] Efficacy of a house dust mite-induced mouse model for allergen-specific immunotherapy in allergic rhinitis
    Jee, Hye Mi
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2022, 10 (04): : 187 - 188
  • [49] Effectiveness and safety of allergen-specific immunotherapy in allergic rhinitis and asthma patients: Experience of a Portuguese immunoallergology department
    Heleno, S. A.
    Afonso, M.
    Silva, J.
    Silva, R.
    Pinto, C.
    Gomes, T.
    ALLERGY, 2019, 74 : 639 - 639
  • [50] Development of a house dust mite-induced mouse model for allergen-specific immunotherapy in allergic rhinitis
    Kim, Seok Min
    Kim, Ji An
    Kim, Hwan Soo
    Yoon, Jong-Seo
    Kim, Hyun Hee
    Chun, Yoon Hong
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2022, 10 (04): : 195 - 201